| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Comprehensive loss | -34,305 | -100,911 | -86,657 | -75,214 |
| Basic eps | - | - | -0.87 | -1.15 |
| Diluted eps | - | - | -0.87 | -1.15 |
| Basic average shares | - | - | 81,344,134 | 66,420,063 |
| Diluted average shares | - | - | 81,344,134 | 66,420,063 |
| Net loss per share, basic (in dollars per share) | -0.34 | - | - | - |
| Net loss per share, diluted (in dollars per share) | -0.34 | - | - | - |
| Weighted-average shares outstanding, basic (in shares) | 81,784,499 | - | - | - |
| Weighted-average shares outstanding, diluted (in shares) | 81,784,499 | - | - | - |
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)